Molecular Formula | C29H37NO3 |
Molar Mass | 447.61 |
Storage Condition | 2-8°C |
Overview | the chemical structure of linosazone is similar to that of Ru486, and it is a C11, C17 substituted compound. Its structural difference with mifepristone is only in the C17α substituent, which is related to the strength of the anti-glucocorticoid activity, the 17-propenyl Group of the linolesone and the 17-propynyl Group of the mifepristone. Small changes in the structure of this point well differentiated antiprogestin and antiglucocorticoid activity. The antiprogestin effect was 1-3 times of that of mifepristone, but the antiglucocorticoid activity was only 10% of that of mifepristone. It has no progestogen-like effect and has little affinity for the estrogen, androgen and mineralocorticoid receptors, and therefore does not exhibit the corresponding hormonal and antihormonal activity. It can promote the synthesis and release of PG in decidual gland cells of early pregnant women, inhibit the catabolism of PG, increase the local PG content, and play a role in terminating early pregnancy. |
Application of | linosolone can promote the synthesis and release of PG in decidual gland cells of early pregnant women, and inhibit the catabolism of PG, so that the local PG content increased, play the role of anti-early pregnancy. Both liromedione and RU486 can cause estrus cycle disturbance in rats. Rituxone can reversibly inhibit the ovulation of rats and monkeys, and at the same time, the LH of animals in preestrus was slightly increased, while the LH peak was obviously inhibited before ovulation. |